Who is sponsoring NCT03880851?

NCT03880851 is sponsored by University Hospital Tuebingen.

What drugs are being tested in NCT03880851?

Interventions in NCT03880851: Plan adaptation of Radiation Treatment in case of anatomical changes.

What condition does NCT03880851 study?

NCT03880851 studies Prostate Cancer.

Is NCT03880851 still recruiting?

NCT03880851 is currently status unknown. Last updated 20 March 2019.

Last reviewed 2019-03-20 · How we verify

NCT03880851: Mbase_HyPro

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MR-based Hypofractionated Adaptive IGRT of Prostate Cancer (M-base HyPro 2.0)

Status unknown NA Last updated 20 March 2019

What this trial tests

NA trial testing Plan adaptation of Radiation Treatment in case of anatomical changes in Prostate Cancer in 78 participants. Status unknown.

Timeline

23 January 2019

Primary endpoint
31 January 2024

31 January 2024

Quick facts

Lead sponsor	University Hospital Tuebingen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	23 January 2019
Primary completion	31 January 2024
Estimated completion	31 January 2024
Sites	1 location across Germany

Drugs / interventions tested

Plan adaptation of Radiation Treatment in case of anatomical changes

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University Hospital Tuebingen

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single-centre single-armed, non-randomized interventional phase II-study of hypofractionated image-guided radiotherapy "IGRT" with weekly magnetic resonance imagings "MRI" for personalized adaptation of the treatment plan depending on individual MR-anatomy of prostate/organ at risks "OAR" during course of IGRT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI.
Almansour H, Afat S, Fritz V, Schick F, et al · · 2021 · cited 17× · PMID 33810410 · DOI 10.3390/cancers13071533
Longitudinal monitoring of Apparent Diffusion Coefficient (ADC) in patients with prostate cancer undergoing MR-guided radiotherapy on an MR-Linac at 1.5 T: a prospective feasibility study.
Almansour H, Schick F, Nachbar M, Afat S, et al · · 2023 · cited 7× · PMID 37341194 · DOI 10.2478/raon-2023-0020

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University Hospital Tuebingen trials

Trials by the same sponsor.

NCT07378670 — DEfeating PEnile CAncer-2 · NA · recruiting
NCT07276503 — Verification of a New Predictive Delirium Score in Adults With Elective Cardiac Valve or Bypass Surgery With Perioperati · not yet recruiting
NCT07411365 — Dual-task Cognitive-motor Telerehabilitation in Persons With PD-MCI · NA · not yet recruiting
NCT06953791 — Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Pat · Phase 2 · recruiting
NCT07378891 — Artificial-Intelligence-based Early Detection of Diabetic Retinopathy (FUNDUS AI) · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03880851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Tuebingen
Last refreshed: 20 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing